drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (gene-modified autologous T cells)
drug_description
Patient-derived T lymphocytes genetically engineered to express a chimeric antigen receptor that recognizes a tumor-associated antigen and activates T-cell effector functions via CD3ζ and a costimulatory domain (e.g., CD28 or 4-1BB), leading to cytotoxic killing, cytokine release, expansion, and persistence.
nci_thesaurus_concept_id
C200766
nci_thesaurus_definition
Autologous T-lymphocytes engineered to contain one or more chimeric antigen receptors (CARs) that specifically target one or more specific antigen(s).
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes are genetically engineered to express a chimeric antigen receptor that binds a tumor-associated antigen independent of MHC, initiating CD3ζ signaling with a costimulatory domain (e.g., CD28 or 4-1BB) to activate cytotoxic killing, cytokine release, proliferation, and persistence of the T cells to eliminate antigen-expressing tumor cells.
drug_name
Autologous CAR T cells
nct_id_drug_ref
NCT05024175